Poland again improved its score in the W.A.I.T. survey in terms of accessibility to innovative drugs, moving up one place and ranking 20th among the 36 European countries surveyed, with a score of 41 percent of available therapies. We are separated from the European average of 43 percent by two countries - Slovenia (42 percent) and Finland (43 percent). Recall that a year ago Poland rose from 25th to 21st place with a score of 36 percent. Today, 69 out of 167 innovative drug technologies are reimbursed in Poland, but as much as 83 percent of them are reimbursed only to a limited group of patients. This result is worse than a year ago by as much as 5 p.p., when the restrictions were at 78 percent. The time from registration to reimbursement, on the other hand, has shortened - from 827 days a year ago to 804 days in the current survey, but this is still one of the worst results a in the entire list. Only four countries are behind us - Serbia, Bosnia, Turkey and Malta.
Poland moves up one "notch"
Poland is steadily improving its score in the W.A.I.T. (Waiting to Access Innovative Therapies) survey, which celebrates its 20th anniversary this year. It is the largest analysis of access to innovative drugs and a measure of waiting times in European countries. The results of the survey have been published since 2004 by the European Federation of Pharmaceutical Industries and Associations. Poland recorded a historic advance in last year's ranking - we moved from 25th to 21st place. At that time, 59 out of 168 therapies were reimbursed in our country. This year, with 69 out of 167 reimbursed therapies, we rank 20th among 36 European countries. The podium is unchanged - Germany remains the leader with 147 available therapies, followed closely by Italy (129) and Austria (126). Poland is ahead of Hungary and Slovakia, among others, but our other neighbor, the Czech Republic, for example, ranks as high as 7th in the W.A.I.T. list.
- Access to innovative drug technologies in Poland is improving. Similar information was provided by updated data announced in May from the Access GAP platform, which analyzes access to innovative therapies and diagnostic solutions in the Visegrad countries. According to them, the Czech Republic is also well ahead of Slovakia, Poland and Hungary, respectively. Poland's good result in the W.A.I.T. list proves that we are moving in the right direction and, thanks to positive reimbursement decisions, we are catching up in terms of Polish patients' access to innovative therapies. At the same time, a detailed analysis of the W.A.I.T. results shows that older drugs are still m...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
